The Lidera Health Transfer Fund, initially endowed with €60 million in a co-investment format with specialized private investors, supports projects related to health sciences, financing everything from scientific validation experiments for companies emerging from research in Catalonia to subsequent investments carried out by specialized venture capital funds.

The instrument is structured to support two types of operations:

• A first tranche of up to €500,000 (killer experiment phase)

• A second tranche of up to €2,000,000 (post-killer experiment phase)

• Increase the number of new companies created from research.

• Promote areas such as advanced therapies, oncology, and medical technologies, which generate extremely high-quality science but require initial technical validation through the first experiments to determine viability (killer experiments).

• Provide projects with strong potential, promising outlooks, and strategic impact for Catalonia with the necessary financial resources at the earliest stages, supporting them from day one to make them attractive for private investment.

• Funding the “killer experiments” therefore constitutes the first key step in the valorization process.

• Projects submitted by accredited private investors, both national and international.

• Catalan spin-offs originating from universities and research centers.

• Other non-spin-off Catalan companies, exclusively for financing in the post–killer experiment phase.

• Access to post–killer experiment funding requires that the project has an already established company.